Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Semma Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10995
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar levels. Semma’s regenerative medicine therapies and stem cell technologies with delivery systems are designed to protect cells from the immune system. The company focuses on combining active cells with a state-of-the-art cell delivery technology to cure patients with diabetes. It has offices in Cambridge and Providence, the US. Semma Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Semma Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Semma Therapeutics Raises USD114 Million in Series B Financing 10
Semma Therapeutics Raises Funds through Venture Financing 12
Semma Therapeutics Raises USD44 Million in Series A Financing 13
Partnerships 14
Semma Therapeutics Enters into Agreement with Novartis 14
Licensing Agreements 15
Semma Therapeutics Enters into Licensing Agreement with Harvard University 15
Acquisition 16
Semma Therapeutics Acquires CytoSolv 16
Semma Therapeutics Inc – Key Competitors 17
Semma Therapeutics Inc – Key Employees 18
Semma Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
May 10, 2018: Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and President 20
Other Significant Developments 21
Mar 22, 2017: Semma Therapeutics Receives Investment from JDRF T1D Fund 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Semma Therapeutics Raises USD114 Million in Series B Financing 10
Semma Therapeutics Raises Funds through Venture Financing 12
Semma Therapeutics Raises USD44 Million in Series A Financing 13
Semma Therapeutics Enters into Agreement with Novartis 14
Semma Therapeutics Enters into Licensing Agreement with Harvard University 15
Semma Therapeutics Acquires CytoSolv 16
Semma Therapeutics Inc, Key Competitors 17
Semma Therapeutics Inc, Key Employees 18
Semma Therapeutics Inc, Other Locations 19
Semma Therapeutics Inc, Subsidiaries 19

List of Figures
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Construction Bank Corp:企業の戦略・SWOT・財務情報
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Open Text Corporation (OTEX):企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Microbot Medical Inc (MBOT):企業の財務・戦略的SWOT分析
    Summary Microbot Medical Inc (Microbot), formerly StemCells Inc, is a pre-clinical medical device company that researches, designs and develops micro-robotics assisted medical technologies for minimally invasive surgeries. The company’s product candidates comprises Self Cleaning Shunt, intended for …
  • Bank of Japan (8301):企業の財務・戦略的SWOT分析
    Bank of Japan (8301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Alimera Sciences Inc (ALIM):医療機器:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …
  • Saudi Electricity Co:発電所・企業SWOT分析
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Extendicare Inc.:企業の戦略・SWOT・財務分析
    Extendicare Inc. - Strategy, SWOT and Corporate Finance Report Summary Extendicare Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • China Huaneng Group:企業の発電所・SWOT分析2018
    China Huaneng Group - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • SYNNEX Corp (SNX):企業の財務・戦略的SWOT分析
    SYNNEX Corp (SNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Graham Holdings Company (GHC):企業の財務・戦略的SWOT分析
    Graham Holdings Company (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Avanir Pharmaceuticals Inc:企業の戦略的SWOT分析
    Avanir Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Surfnet:企業の戦略的SWOT分析
    Surfnet - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Vect-Horus SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vect-Horus SAS (Vect-Horus) is a biotechnology company that designs and develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into organs including the brain and tumors. The company combines molecules of interest to peptide-vectors that targets receptor mediate …
  • FuelCell Energy Inc (FCEL)-エネルギー分野:企業M&A・提携分析
    Summary FuelCell Energy, Inc. (FuelCell Energy) is an integrated fuel cell company that designs, manufactures, installs, operates, and services stationary fuel cell power plants for distributed power generation. It offers proprietary fuel cell products based on Direct FuelCell (DFC) carbonate fuel c …
  • Petrogrand AB:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrogrand AB (Petrogrand), formerly Malka Oil AB is an oil and gas company that acquires, explores and produces crude oil and natural gas assets. The company carries out management and refining of Russian oil assets. It holds interests in the Nizhne-Paninsky license area located in northwes …
  • NanoCarrier Co Ltd (4571):企業の財務・戦略的SWOT分析
    Summary NanoCarrier Co Ltd (NanoCarrier) is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, NC-4016, NC-6300, VB-111, NC-6201 and NK105. It offers siRNA micelle, protein micelle, DACH-plat …
  • Beaver-Visitec International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beaver-Visitec International Inc (BVI) is a manufacturer, developer and marketer of ophthalmic and other specialty microsurgical products. The product portfolio of the company includes knives, cannulae and fluid control products, electrosurgical devices, microsurgical instruments, drapes and …
  • CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報
    Summary CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and second …
  • Mycenax Biotech Inc (4726):企業の財務・戦略的SWOT分析
    Summary Mycenax Biotech Inc (Mycenax) is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company provides pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, …
  • TAS Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary TAS Energy, Inc. (TAS), formerly Turbine Air Systems, Ltd., offers clean and modular energy solutions. The company designs, manufactures and supplies turbine inlet chilling systems for power augmentation; modular utility systems for air cooling; waste heat/geothermal systems for power genera …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆